Skip to main content
SpringerLink
Log in

Bevacizumab: NCCN updates guidelines for metastatic breast cancer

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bevacizumab: NCCN updates guidelines for metastatic breast cancer. Pharmacoecon. Outcomes News 616, 4 (2010). https://doi.org/10.2165/00151234-201006160-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-201006160-00007

Keywords

Search

Navigation